



(51) International Patent Classification:

C07D 403/14 (2006.01) *A61K 31/4725* (2006.01)
C07D 417/14 (2006.01) *A61P 27/00* (2006.01)
C07D 471/04 (2006.01)

(21) International Application Number:

PCT/GB2014/051592

(22) International Filing Date:

23 May 2014 (23.05.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/826,596 23 May 2013 (23.05.2013) US
 61/865,756 14 August 2013 (14.08.2013) US

(71) Applicant: **KALVISTA PHARMACEUTICALS LIMITED** [GB/GB]; Building 227, Tetricus Science Park, Porton Down, Sailsbury SP4 0JQ (GB).(72) Inventors: **DAVIE, Rebecca Louise**; Kalvista Pharmaceuticals Limited, Building 227, Tetricus Science Park, Porton Down, Sailsbury SP4 0JQ (GB). **EDWARDS, Hannah Joy**; Kalvista Pharmaceuticals Limited, Building 227, Tetricus Science Park, Porton Down, Sailsbury SP4 0JQ (GB). **EVANS, David Michael**; Kalvista Pharmaceuticals Limited, Building 227, Tetricus Science Park, Porton Down, Sailsbury SP4 0JQ (GB). **HODGSON, Simon Teanby**; Kalvista Pharmaceuticals Limited, Building 227, Tetricus Science Park, Porton Down, Sailsbury SP4 0JQ (GB). **MILLER, Iain**; Sygnature Discovery Ltd, BioCity, Pennyfoot Street, Nottingham NG1 1GF (GB). **NOVAK, Andrew Richard**; Sygnature Discovery Ltd, BioCity, Pennyfoot Street, Nottingham NG1 1GF (GB). **SMITH,**

Alun John; Sygnature Discovery Ltd, BioCity, Pennyfoot Street, Nottingham NG1 1GF (GB). **STOCKS, Michael John**; Elm Tree Farm House, 27 Nether End, Great Dalby Leicestershire LE14 2EY (GB).

(74) Agents: **HALLYBONE, Huw George** et al.; Carpmaels & Ransford LLP, One Southampton Row, London WC1B 5HA (GB).


(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: HETEROCYCLIC DERIVATES



(I)

(57) **Abstract:** The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.